CAPS Medical

CAPS Medical is a clinical-stage medical device company developing cold plasma-based technologies for minimally invasive cancer treatments. The organization's primary product, PlasmaSure, enables endoscopic tumor ablation designed to selectively destroy solid tumors, such as bladder cancer, while preserving the surrounding healthy tissue. The enterprise recently completed a clinical study utilizing its technology to treat nearly 70 tumors, successfully destroying 85 percent of the targeted masses after a single treatment with no local recurrences observed during a one-year follow-up period. The core technology was licensed from academic and medical institutions including Technion and the Rambam Health Care Campus, while the leadership team brings prior experience from medical device firms like OSSIO and Rainbow Medical. CAPS Medical was co-founded by chief executive officer Ilan Uchitel, though the exact year of the company's formal establishment remains undisclosed.